Kings Path Partners LLC Trims Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Kings Path Partners LLC trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,733 shares of the medical instruments supplier’s stock after selling 275 shares during the quarter. LeMaitre Vascular accounts for 0.7% of Kings Path Partners LLC’s holdings, making the stock its 26th largest holding. Kings Path Partners LLC owned about 0.08% of LeMaitre Vascular worth $1,634,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Conestoga Capital Advisors LLC raised its position in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after acquiring an additional 36,850 shares in the last quarter. Copeland Capital Management LLC raised its holdings in LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after purchasing an additional 11,318 shares in the last quarter. State Street Corp raised its holdings in LeMaitre Vascular by 3.6% in the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after purchasing an additional 28,525 shares in the last quarter. Congress Asset Management Co. lifted its position in shares of LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after buying an additional 18,295 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after buying an additional 23,443 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 1.1 %

Shares of LMAT stock traded up $1.04 during mid-day trading on Monday, reaching $92.78. The stock had a trading volume of 36,704 shares, compared to its average volume of 147,981. LeMaitre Vascular, Inc. has a 1-year low of $54.03 and a 1-year high of $109.58. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 50.70, a PEG ratio of 2.47 and a beta of 0.96. The business’s fifty day moving average is $98.44 and its 200-day moving average is $90.91.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Oppenheimer reissued an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. Barrington Research boosted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.